Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,916,901 papers from all fields of science
Search
Sign In
Create Free Account
sampatrilat
Known as:
N-(1-(2-carboxy-3-(N(2)-mesyllysylamino)propyl)-1-cyclopentylcarbonyl)tyrosine
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Broader (3)
Mesylates
Protease Inhibitors
Tyrosine
Narrower (1)
UK 81,252
analogs & derivatives
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Molecular Basis for Omapatrilat and Sampatrilat Binding to Neprilysin—Implications for Dual Inhibitor Design with Angiotensin-Converting Enzyme
U. Sharma
,
G. Cozier
,
E. Sturrock
,
K. Acharya
Journal of medicinal chemistry
2020
Corpus ID: 216555205
Neprilysin (NEP) and angiotensin-converting enzyme (ACE) are two key zinc-dependent metallopeptidases in the natriuretic peptide…
Expand
2020
2020
Whey-Derived Peptides Interactions with ACE by Molecular Docking as a Potential Predictive Tool of Natural ACE Inhibitors
Yara Chamata
,
K. Watson
,
P. Jauregi
International journal of molecular sciences
2020
Corpus ID: 211024344
Several milk/whey derived peptides possess high in vitro angiotensin I-converting enzyme (ACE) inhibitory activity. However, in…
Expand
2018
2018
Crystal structures of sampatrilat and sampatrilat‐Asp in complex with human ACE – a molecular basis for domain selectivity
G. Cozier
,
S. Schwager
,
Rajni K. Sharma
,
K. Chibale
,
E. Sturrock
,
K. Acharya
The FEBS journal
2018
Corpus ID: 5016222
Angiotensin‐1‐converting enzyme (ACE) is a zinc metallopeptidase that consists of two homologous catalytic domains (known as nACE…
Expand
2016
2016
The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme
Rajni K. Sharma
,
Marlene Espinoza-Moraga
,
+4 authors
K. Chibale
J. Chem. Inf. Model.
2016
Corpus ID: 3599301
Sampatrilat is a vasopeptidase inhibitor that inhibits both angiotensin I-converting enzyme (ACE) and neutral endopeptidase. ACE…
Expand
2003
2003
Beneficial Effects of Sampatrilat, a Novel Vasopeptidase Inhibitor, on Cardiac Remodeling and Function of Rats with Chronic Heart Failure following Left Coronary Artery Ligation
Toshiyuki Maki
,
Y. Nasa
,
K. Tanonaka
,
Masaya Takahashi
,
S. Takeo
Journal of Pharmacology and Experimental…
2003
Corpus ID: 8145873
Sampatrilat is a novel vasopeptidase inhibitor that may offer a greater benefit than traditional angiotensin-converting enzyme…
Expand
2002
2002
Sampatrilat Shire.
K. Allikmets
Current opinion in investigational drugs
2002
Corpus ID: 36238587
Sampatrilat is a dual inhibitor of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE), which is under…
Expand
Highly Cited
1999
Highly Cited
1999
Sustained antihypertensive actions of a dual angiotensin-converting enzyme neutral endopeptidase inhibitor, sampatrilat, in black hypertensive subjects.
G. Norton
,
A. Woodiwiss
,
+4 authors
M. J. Allen
American journal of hypertension
1999
Corpus ID: 24406451
1998
1998
Combined inhibition of neutral endopeptidase and angiotensin‐converting enzyme by sampatrilat in essential hypertension
E. Wallis
,
L. Ramsay
,
J. Hettiarachchi
Clinical pharmacology and therapeutics
1998
Corpus ID: 23830983
1998
1998
Clinical analysis of sampatrilat, a combined renal endopeptidase and angiotensin-converting enzyme inhibitor II: assay in the plasma and urine of human volunteers by dissociation enhanced lanthanide…
R. Venn
,
G. Barnard
,
B. Kaye
,
P. Macrae
,
K. Saunders
Journal of pharmaceutical and biomedical analysis
1998
Corpus ID: 23390796
1996
1996
Renal effects of concurrent E‐24.11 and ACE inhibition in the aorto‐venocaval fistula rat
J. Kirk
,
M. Wilkins
British journal of pharmacology
1996
Corpus ID: 27158932
1 The present studies compare the early renal response to (a) an endopeptidase‐24.11 (E‐24.11) inhibitor (candoxatrilat) (b) an…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE